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ABSTRACT: The causative agent of Legionnaires’ disease,
Legionella pneumophila, grows in environmental amoebae and
mammalian macrophages within a distinct compartment, the
‘Legionella-containing vacuole’ (LCV). Intracellular bacteria are
protected from many antibiotics, and thus are notoriously
diﬃcult to eradicate. To identify novel compounds that restrict
intracellular bacterial replication, we previously developed an
assay based on a coculture of amoebae and GFP-producing L.
pneumophila. This assay was used to screen a pathway-based,
highly diverse chemical library, referred to as the Sinergia
library. In this work, we chose to focus on a group of 11 hit compounds, the majority of which originated from the query
molecule CN585, a compound that targets the protein phosphatase calcineurin. Further studies on 78 related compound variants
revealed crucial structural attributes, namely a triple-ring scaﬀold with a central triazine moiety, substituted in positions 3 and 5
by two piperidine or pyrrolidine rings, and in position 1 by an amine group bearing a single aliphatic chain moiety. The most
eﬀective compound, ZINC00615682, inhibited intracellular replication of L. pneumophila with an IC50 of approximately 20 nM in
Acanthamoeba castellanii and slightly less eﬃciently in Dictyostelium discoideum or macrophages. Pharmacological and genetic
attempts to implicate calcineurin in the intracellular replication of L. pneumophila failed. Taken together, these results show that
the amoebae-based screen and structure−activity relationship analysis is suitable for the identiﬁcation of novel inhibitors of the
intracellular replication of L. pneumophila. The most potent compound identiﬁed in this study targets (an) as yet unidentiﬁed
host factor(s).
KEYWORDS: amoeba, antibiotics, antivirulence, calcineurin, intracellular replication, Legionella, macrophage, pathogen vacuole,
screen, structure−activity relationship (SAR), type IV secretion
Legionella pneumophila is a ubiquitous environmental bacterium
found within a wide range of both natural and artiﬁcial fresh-
water sources.1,2 L. pneumophila resists phagocytosis and
degradation by predatory freshwater amoebae through the
production of numerous “eﬀector” proteins, which are injected
into amoebae via a type IV secretion system (T4SS) and lead to
the formation of the replication-permissive “Legionella-contain-
ing vacuole” (LCV).3−5 As the majority of known eﬀector
protein targets are evolutionarily conserved between both
protozoa and alveolar macrophages,6 L. pneumophila can also
infect human lungs, leading to a potentially fatal pneumonia
known as Legionnaires’ disease.1,2
The mortality rate for Legionnaires’ disease ranges between 2
to 5%, depending on the outbreak.7 Beyond its importance as a
human pathogen, L. pneumophila also subverts host processes
similar to other vacuolar bacteria such as Mycobacterium
tuberculosis.8 Thus, the development of alternative, more
eﬀective methods of treating Legionella infection may also
lead to treatments for Mycobacterium infections, which
themselves kill millions each year.9 As an intracellular pathogen,
L. pneumophila is protected from a number of common
antibacterial treatments, exhibits increased resistance to anti-
biotics,10 and shows signiﬁcantly higher antibiotic resistance
following release from phagocytic cells compared to broth-
grown counterparts.11 Beyond this, chemical decontamination
of man-made water systems often fails to kill L. pneumophila
bacteria that reside within free-living amoebae.12,13
The process of developing novel antibiotics usually involves
compound screens, in which large numbers of chemicals are
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tested for an eﬀect on speciﬁc bacterial targets. Unfortunately,
the use of high-throughput screening in antibacterial develop-
ment remains contentious: large-scale eﬀorts to develop new
broad-spectrum antibiotics met with very limited success, due
to a combination of issues with cell permeability and target
speciﬁcity.14 Another disadvantage of antibiotic compounds is
that selection pressure for the development of drug-resistance
against these compounds is extremely high, essentially forcing
companies to develop drugs that will rarely be used.15 As a
result of these factors, the concept of “antivirulence”
compounds has emerged as an alternate, promising strategy.
These compounds are aimed at speciﬁc pathogenicity
mechanisms such as binding to target cells, uptake processes,
signaling pathways, and the secretion of toxins, as opposed to
directly targeting bacterial replication.16−18
The development of antivirulence compounds has begun, as
seen for example in the injectable antibody Urtoxazumab,
which binds to and neutralizes Shiga-like toxin 2 and is
currently in clinical trials.19 Other examples include salicylidine
derivatives, several of which have been shown to inhibit the
type III secretion system (T3SS) of Salmonella enterica
Typhimurium,20 and Virstatin, an inhibitor of the ToxT
transcription regulator, which prevents the expression of several
Vibrio cholerae virulence factors.21 More recently, nonantibiotic
inhibitors of the Pseudomonas aeruginosa MvfR-regulated
quorum sensing system have been identiﬁed, which bind to
MvfR, block the synthesis of 4-hydroxy-2-alkylquinolone-based
signaling molecules, and thus inhibit acute bacterial patho-
genesis and persistence.22
Targeting virulence-associated pathways is a complex under-
taking, especially when compared to the simplicity of searching
for compounds which prevent replication. This approach
requires either knowledge of the pathogenic process to be
targeted (which can then be assessed via an in vitro system) or
a broader screen to analyze the interaction of the bacterium
with its host cell. Previous work in our group had led to the
development of a novel screening system utilizing L. pneumo-
phila replication within a natural prokaryotic host, Acantha-
moeba castellanii.23 We used this system to screen a pathway-
based highly diverse chemical library, called the Sinergia library,
for chemicals which successfully inhibited intracellular repli-
cation. Here, we report on detailed “hit ﬁnding and chemical
space exploration” studies performed on hits discovered in this
process, resulting in the identiﬁcation and characterization of a
family of advanced hits compounds derived from inhibitors of
the calcineurin protein phosphatase enzyme.
■ RESULTS
Screening for Inhibitors of Legionella Replication. To
identify inhibitors of L. pneumophila intracellular replication,
the Sinergia library was established by utilizing virtual screening
techniques based on “query compounds” known to target
certain pathogen pathways.24 This targeted, highly diverse
library contains 1278 compounds that are grouped and referred
to according to their query compound (e.g., targeting the
protein phosphatase calcineurin or the autophagy pathway)
(manuscript related to the creation and characterization of the
chemical library in preparation).
The Sinergia library was screened for activity against the
intracellular replication of L. pneumophila in A. castellanii using
a previously described assay.23 The compounds were added at a
concentration of 10 or 30 μM, and L. pneumophila replication
was normalized to the range between 0 (kanamycin treatment)
and 1 (vehicle controls). A replication level of 0.5 (i.e., 50%
inhibition) was chosen as the cutoﬀ value to determine any hits
of interest. Using a concentration of 30 μM, 39 hits were
initially identiﬁed (Figure 1A, Table S1). To control for
compound cytotoxicity, we used Alamar Blue viability assays
and tested the response of A. castellanii to these compounds.
Compared to DMSO controls, 9 of the 39 most eﬀective
compounds caused a signiﬁcant change in cell viability (Figure
1A). Taking into consideration the compounds below and very
close to the cutoﬀ, 32 noncytotoxic compounds were
considered further.
The hit compounds were then assessed for their ability to
inhibit the intracellular and extracellular growth (in broth
alone) of L. pneumophila, and the correlation between intra-
and extracellular growth was visualized as a scatter plot (Figure
1). Hits chemically derived from compounds involved in host
cell pathways such as calcineurin (Figure 1B), autophagy
Figure 1. Eﬀect of Sinergia library hit compounds on extra- and
intracellular replication of L. pneumophila. (A) Toxicity of 39 hit
compounds against A. castellanii as determined by Alamar Blue assay.
Red bars indicate compounds causing statistically signiﬁcant altered
viability (t test, p < 0.05). (B−F) Eﬀect of each Sinergia library hit
compound on L. pneumophila replication either in AYE medium
(extracellular) or in A. castellanii amoebae (intracellular). Hits were
divided according to proposed target pathways: calcineurin (B),
autophagy (C), tryptophan biosynthesis (D), proteasome inducers
(E), and others (F). Graphs (A−F) indicate the mean and standard
deviation (SD) of at least triplicate independent assays, with
replication levels normalized to vehicle controls (<0.1% DMSO).
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(Figure 1C), or other processes (Figure 1F) had predominantly
minor eﬀects on extracellular bacterial growth, whereas as
expected, groups of hits chemically derived from compounds
targeting bacterial systems, such as tryptophan biosynthesis
(Figure 1D) or bacterial proteasomes (Figure 1E), tended to
show high degrees of eﬃcacy against extracellular L. pneumo-
phila. As the calcineurin pathway compound group comprised
both the majority of hits and appeared to act in a manner
supporting an antivirulence eﬀect, we elected to further
characterize this group. However, the annotation of hits to
calcineurin does not imply per se that the compounds directly
aﬀect this pathway (see below).
Characterization of Hits Chemically Derived from
Compounds Targeting the Calcineurin Pathway. Follow-
ing the initial screen, we retested 12 calcineurin compounds (11
hits and 1 borderline case) for eﬃcacy based on the structural
background. The compounds from the calcineurin pathway
were derived from two distinct query molecules, the
pyrazolopyrimidine moiety and CN585 compound (Figure
2A). A pyrazolopyrimidine derivative, compound NCI3,
indirectly inhibits calcineurin overproduction,25 and CN585 is
a rationally designed derivative of 6-(3,4-dichloro-phenyl)-4-
(N,N-dimethylaminoethylthio)-2-phenyl-pyrimidine, which has
been reported to reversibly inhibit calcineurin activity with an
IC50 of 3.8 μM.
26 The majority of eﬀective hits (8 of 12)
originated from the CN585 query molecule. However, among
the hits identiﬁed, the degree of replication inhibition did not
correlate with the underlying scaﬀold (pyrazolopyrimidine or
CN585) (Figure 2B, Table S2).
In an attempt to further investigate the mode of action of
these compounds, we examined the time dependence of
compound treatment. The prior process of screening had
involved the simultaneous addition of compounds and L.
pneumophila; additional testing examined the eﬀect of
pretreating the amoebae with compound (for 30 min, infection
then proceeded in media alone) and post-treatment (infection
in media only, followed by compound addition after 30 min).
The majority of compounds were eﬀective only when present at
the time of infection (Figure 2C). The sole compound active in
post-treatment, ZINC03163860, was also observed to be
slightly cytotoxic following further testing (Figure 2D), which
may suggest oﬀ-target eﬀects. A single compound,
ZINC09306182, was an eﬀective inhibitor of bacterial
replication following pretreatment. The reason behind this is
unclear, although it may relate to the signiﬁcant diﬀerence in
chemical structure compared to the other hits from the
calcineurin pathway (see below).
In order to conﬁrm the eﬃcacy of these compounds, we
cross-screened for those which inhibited the intracellular
replication of L. pneumophila within the social amoeba D.
discoideum (Figure 2E). The majority of compounds eﬀective in
A. castellanii also prevented replication in D. discoideum;
however, a group of four compounds were relatively ineﬀective.
To correlate the observed defects in the intracellular replication
of L. pneumophila with altered vesicle traﬃcking, LCV
formation, or pathogen vacuole composition, we attempted to
determine alterations in the cellular localization of various small
GTPases of the Rab family (Rab1, Rab5a, Rab7, Rab8a,
Rab11b, and Rab14) following treatment with ZINC09306182
and L. pneumophila infection (Figure S1). However, compared
to untreated cells, no signiﬁcant diﬀerences in Rab localization
could be observed in D. discoideum infected with L. pneumophila
wild-type or a ΔicmT mutant strain.
Plotting the inhibition of intracellular replication versus cell
viability indicated a fairly strong correlation for D. discoideum
(Figure 2F), in stark contrast to A. castellanii (Figure 2D). This
is potentially due to the extended time required for a full
infection round in D. discoideum (7 days) as compared to A.
castellanii (3 days), suggesting that long-term treatment with
the compounds may be cytotoxic. In summary, the calcineurin
compounds derived from two diﬀerent query structures
inhibited the intracellular growth of L. pneumophila in triazine
when present at the initiation of infection and also impaired
bacterial replication in D. discoideum.
Structure−Activity Relationship Analysis of the Hits
Chemically Derived from Compounds Targeting the
Calcineurin Pathway. For the 12 calcineurin hit compounds
identiﬁed we performed structure−activity relationship (SAR)
studies to develop an optimized set of molecules restricting
Legionella infection. As mentioned above, the initial Sinergia
library design utilized two diﬀerent queries for compounds
targeting the “calcineurin pathway (Figure 2A), which were
further used as a basis to produce an extended set of 78
compounds for the subsequent rounds of screening (Figure
Figure 2. Characterization of the hits from the calcineurin pathway.
(A) Hits within the calcineurin group were derived from two chemical
queries, CN585 (blue diamonds) and pyrazolopyrimidine (black
squares). (B) Comparison of compound eﬃcacy (30 μM) against
intracellular (A. castellanii) and extracellular L. pneumophila, segregated
by the originating scaﬀold. (C) Comparison of compound eﬃcacy (30
μM) when treating A. castellanii 30 min before or after infection with
L. pneumophila. The majority of compounds needed to be present at
the same time as infection occurs. (D) Comparison of eﬃcacy versus
toxicity (30 μM) in A. castellanii indicates that only one compound,
ZINC03163860, was toxic to amoebae over the time scale of L.
pneumophila infection. (E) Comparison of compound eﬃcacy (30
μM) against intracellular replication in A. castellanii and D. discoideum
reveals generally reduced eﬃcacy in treating D. discoideum. (F)
Comparison of eﬃcacy versus toxicity (7.5 μM) in D. discoideum
indicates that, unlike in A. castellanii, eﬃcacy correlates with
cytotoxicity. All graphs (B−F) indicate the mean and SD of at least
three independent experiments.
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Figure 3. Structure−activity relationship analysis of hits from the calcineurin pathway. (A) Screening results of the initial 78 compounds derived
from the 2 original query structures (CN585, pyrazolopyrimidine) indicate that the majority did not have an eﬀect on replication. The graph shows
the mean and SD of at least four separate experiments. (B, C) Structures of the 12 best hits derived from the CN585 or pyrazolopyrimidine queries,
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3A). The 12 most eﬀective compounds revealed that hits
derived from the CN585 query were more numerous and
showed greater homology between chemical structures than
those originating from the pyrazolopyrimidine scaﬀold (Figure
3B,C). For this reason we chose to focus on the CN585
variants.
A 2D chemical similarity search (similarity threshold >70%)
led us to identify common features among the CN585 variants
in the ZINC database, and 20 analogues with molecular
Figure 3. continued
respectively. (D) Regions of similarity for the compounds in (B) were determined, and compounds with minor chemical modiﬁcations were then
tested for their eﬀect on L. pneumophila replication within A. castellanii. (E) The most eﬀective inhibitors of intracellular bacterial replication
(advanced hits compounds) share several structural features: a triple-ring structure with a central triazine substituted at positions 3 and 5 by two
piperidine or pyrrolidine heterocycles (red) and a nitrogen group at position 1 (blue), which is substituted by a hydrophobic aliphatic chain moiety
(green). (F) Alterations to this pattern, such as the absence of substituents on the nitrogen atom, or its inclusion in a hydrazine group or in an
aliphatic hydroxylated ring, render the compound unable to inhibit L. pneumophila replication.
Figure 4. Characterization of advanced hits compounds. (A−D) Dose−response curves of advanced hits compounds for intracellular replication of
L. pneumophila in A. castellanii. (E) Comparison of the eﬃcacy of advanced hits and ineﬀective compounds (3 μM) on intracellular replication in A.
castellanii (red) and extracellular replication (green). The graph indicates the mean and SD of at least four separate experiments (**p < 0.01, ***p <
0.001; Student’s t test). (F) Eﬃcacy of compounds on intracellular replication in D. discoideum at 30 or 3 μM, normalized to the vehicle. The graph
indicates the mean and SD of three experiments. (G) Eﬃcacy of compounds on intracellular replication in RAW 264.7 macrophages, at 30, 15, or 3
μM, normalized to vehicle control. The graph indicates the mean and SD of six separate experiments. (H) Eﬀects of advanced hits compounds on
the intracellular growth of L. pneumophila in A. castellanii at 30 °C, as determined by CFU 3 days postinfection. (I) Cytotoxicity determination of
advanced hits compounds toward A. castellanii, D. discoideum, or RAW 264.7 macrophages after 6 h, using the Presto Blue cell viability assay. The
graph indicates the mean and SD of (H) three samples or (I) six samples.
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variations were chosen for further testing (Figure S2). Results
from intracellular growth assays with A. castellanii indicated that
the compound eﬃcacy of a subset of molecules derived from
the 20 CN585 compound analogues increased signiﬁcantly
(Figure 3D). Integration of this information led to the
determination of the ideal structural attributes comprising a
triazine moiety, substituted in positions 3 and 5 by two
piperidine or pyrrolidine rings, respectively, and in position 1
by an amine group bearing a single aliphatic chain substituent
moiety. In particular, diﬀerent substituents from piperidine or
pyrrolidine rings at positions 3 and 5 of the triazine moiety
remarkably aﬀected the capability of compounds to inhibit the
intracellular replication of L. pneumophila (Figure 3E). Further
analysis revealed the importance of the substitution patterns on
the nitrogen atom in position 1 of the triazine ring. Indeed,
compounds bearing a single lipophilic aliphatic chain as a
substituent on the position 1 nitrogen displayed a considerably
higher activity than those having a free nitrogen, a nitrogen
substituted with hydrophilic groups (amine, amide, and
hydroxyl ethyl), or tertiary nitrogen atoms (closed within the
ring or diﬀerently substituted) (Figure 3F). Taken together,
SAR analysis identiﬁed molecules and their structural
determinants, which inhibited the intracellular replication of
L. pneumophila much more eﬃciently than the original hit
compounds. Four eﬀective and two ineﬀective compounds were
then taken as advanced hits and control compounds,
respectively, for further characterization.
Characterization of Advanced Hits Compounds. Using
the four advanced hits compounds (Figure 3E) and two control
compounds (Figure 3F), we set out to characterize these
molecules, which had been developed through structural
modiﬁcations of CN585. To this end, we determined dose−
response relationships of the four advanced hits compounds for
the intracellular replication of L. pneumophila in A. castellanii
(Figure 4A−D, Table S3). Three of them exhibited IC50 values
of between 1 and 5 μM, and ZINC00615682 was an extremely
eﬃcient inhibitor with an IC50 of approximately 20 nM (Table
1). At 3 μM, we observed that the advanced hits compounds
were neither toxic to A. castellanii nor able to inhibit the
extracellular growth of L. pneumophila but did strongly inhibit
intracellular replication (Figure 4E). Comparative testing in D.
discoideum (Figure 4F) or RAW 264.7 macrophages (Figure
4G) indicated that intracellular bacterial replication in these
host cells was less sensitive to compound treatment because,
with the exception of the highly eﬃcacious ZINC00615682, a
decrease in replication was seen at 30 μM but not at 3 μM.
These ﬁndings are similar to previously observed diﬀerences in
the eﬃcacy of anti-Legionella compounds in diﬀerent host
models.23
In order to correlate the production of GFP as a measure of
bacterial growth with a more direct assay, we determined
colony-forming units (CFU) of L. pneumophila growing
intracellularly in A. castellanii upon exposure to the advanced
hits compounds after 3 days (Figure 4H). This approach
revealed that the four most potent advanced hits compounds
(shown in Figure 3E) prevented intracellular bacterial growth
almost completely. Thus, the production of GFP indeed
correlates very well with bacterial replication as measured by
CFU. Moreover, we also assessed the cytotoxicity of these
compounds against A. castellanii, D. discoideum, and RAW 264.7
macrophages (Figure 4I). Compared to the vehicle control, the
advanced hits compounds were not signiﬁcantly cytotoxic to
any of the phagocytes. In summary, the dose−response analysis
performed for the four advanced hits compounds revealed that
ZINC00615682 is a very eﬀective inhibitor of L. pneumophila
intracellular replication, preventing growth in A. castellanii with
a low IC50 of ∼20 nM.
Calcineurin Does Not Play a Signiﬁcant Role in L.
pneumophila Replication. A number of the highly eﬀective
inhibitors of L. pneumophila replication characterized above are
based on the molecule CN585, a noncompetitive inhibitor of
calcineurin.26 Thus, we presumed that our advanced hits
compounds would be exerting a similar eﬀect, and we
attempted to determine whether calcineurin indeed played a
role in their mechanism of action. Calcineurin is a
heterodimeric protein phosphatase consisting of a cal-
modulin-binding catalytic subunit (calcineurin A) and a Ca2+-
binding regulatory subunit (calcineurin B).
We ﬁrst analyzed the eﬀect of known inhibitors and
activators of calcineurin to determine any relationship to L.
pneumophila intracellular replication. The calcineurin inhibitor
cyclosporin A27 did not have a major eﬀect on L. pneumophila
replication within A. castellanii or D. discoideum (showing
approximately 20% inhibition at 10 μM) (Figure 5A). However,
at a relatively high IC50 (∼30 μM), cyclosporin A reduced the
replication of L. pneumophila in RAW 264.7 macrophages,
when present at the time of infection. Furthermore, cyclosporin
A did exert a relatively strong inhibitory eﬀect on the
extracellular growth of L. pneumophila (IC50 2 μM, 95%CI:
1.4−3.1 μM), suggesting that it was acting as an oﬀ-target
antibiotic.
The calcineurin inhibitor quercetin28 inhibited the replication
of L. pneumophila in A. castellanii only at high concentrations
(IC50 ∼100 μM, 95%CI: 30−300 μM) with limited or no
eﬀects on infected D. discoideum or macrophages and on
extracellular bacteria (Figure 5B). Moreover, the calcineurin
activator chlorogenic acid29 had no signiﬁcant eﬀect on intra- or
extracellular replication of L. pneumophila (Figure 5C).
Together, pharmacological experiments suggested that the
protein phosphatase calcineurin does not play a signiﬁcant role
in the intracellular replication of L. pneumophila.
To further explore whether calcineurin might play a role in
the intracellular growth of L. pneumophila, we depleted the
enzyme in human A549 cells using RNA interference. To this
end, the two individual subunits of calcineurin encoded by the
PPP3CB and PPP3R1 genes were depleted separately, after
which the intracellular replication of L. pneumophila was
assessed (Figure 5D). However, no eﬀect on the intracellular
replication of L. pneumophila was observed upon depletion of
the individual calcineurin subunits. Western blot analysis of the
depletion eﬃciency of the calcineurin catalytic subunit PPP3CB
revealed a reduction of approximately 60% under the
Table 1. IC50 Values for Inhibition of L. pneumophila
Replication in A. castellanii by Advanced Hits and Control
Compounds
compound IC50 (M) 95% conﬁdence intervals (M)
ZINC00615682 1.97 × 10−8 3 × 10−12−1.3 × 10−4
ZINC95411800 1.05 × 10−6 6.5 × 10−7−1.6 × 10−6
ZINC95446205 1.1 × 10−6 6.3 × 10−7−1.9 × 10−6
ZINC83911676 4.63 × 10−6 1.8 × 10−6−1.2 × 10−5
ZINC24053706 no eﬀect no eﬀect
ZINC24052827 no eﬀect no eﬀect
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Figure 5. Calcineurin is not involved in L. pneumophila replication. (A−C) Dose−response curves plot (mean and SD of at least seven separate
experiments) of L. pneumophila replication versus vehicle control (<0.5% DMSO), in media (extracellular), amoebae (A. castellanii or D. discoideum),
or RAW 264.7 macrophages. (A) The calcineurin inhibitor cyclosporin A exhibits an antibiotic eﬀect against L. pneumophila (IC50 2 μM, 95% CI:
1.4−3.1 μM) and, at higher concentrations, inhibits replication within RAW 264.7 macrophages (IC50 ∼30 μM). (B) The calcineurin inhibitor
quercetin shows the inhibition of intracellular replication of L. pneumophila in A. castellanii at relatively high concentrations (IC50 ∼100 μM). (C)
The calcineurin activator chlorogenic acid has no eﬀect on L. pneumophila replication. (D) Replication of L. pneumophila in A549 epithelial cells after
depletion by RNAi of individual calcineurin subunits (PP3CB, PP3R1) or the small GTPase Arf1. The graph shows the mean and SD of triplicate
experiments (**p < 0.01; Student’s t test). (E) Replication of L. pneumophila in D. discoideum lacking coronin A (green) or depleted by RNAi for
calcineurin A (red, CNA) or calcineurin B (blue, CNB) subunits, as normalized to the respective control strains (gray). The graph indicates the
mean and 95% CI of at least triplicate experiments (*p < 0.05, **p < 0.01, ***p < 0.001; Student’s t test). (F, G) Replication of L. pneumophila in D.
discoideum wild type or strains depleted for calcineurin subunits by siRNA following treatment with (F) quercetin, cyclosporin A, or chlorogenic acid
(15 μM) or (G) CN585-derived advanced hits or control compounds (3 μM). Replication was normalized to the vehicle control and compared to
Ax2 wild-type amoebae (**p < 0.01, ***p < 0.001). (H) The calcineurin compounds (CN585, white; pyrazolopyrimidine moiety, blue; controls,
gray) do not signiﬁcantly aﬀect calcineurin activity in vitro at 30 μM concentration. The graph shows the mean and SD of at least three replicate
experiments (statistics: one way ANOVA, Gaussian approximation).
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conditions used (Figure S3). As a positive control, we depleted
the small GTPase ARF1, which promotes the intracellular
growth of L. pneumophila.30 As expected, the depletion of ARF1
led to a reduction in replication eﬃciency.
We also assessed intracellular bacterial replication in D.
discoideum strains with the RNAi-mediated knock-down of
calcineurin subunits A and B. Here, the replication eﬃciency of
L. pneumophila was slightly but signiﬁcantly reduced (Figure
5E). Finally, D. discoideum strains lacking the upstream
calcineurin activator coronin exhibited a small but signiﬁcant
increase in L. pneumophila replication (Figure 5E), in line with
previous studies that have also observed increased replication of
L. pneumophila within coronin-knockout D. discoideum.31,32
Taken together, these results suggest that the absence of
(active) calcineurin does not cause a major change in the
intracellular replication of L. pneumophila.
Furthermore, we used D. discoideum strains depleted of
calcineurin subunits to analyze the eﬀects on the intracellular
replication of L. pneumophila of compounds known or
presumed to target calcineurin. As previously seen in wild-
type D. discoideum, no obvious changes in intracellular bacterial
replication were seen following treatment of the amoebae with
cyclosporin A, quercetin, or chlorogenic acid (Figure 5F).
Likewise, the advanced hits compounds developed previously
(Figures 3E and 4) but not the control compounds (Figures 3F
and 4) still blocked intracellular replication in D. discoideum
depleted of calcineurin (Figure 5G). These ﬁndings indicate
that the advanced hits compounds target factors in the cell,
which are not implicated in the calcineurin pathway.
Interestingly, drug treatment of D. discoideum depleted of
calcineurin led to a further (synergistic) reduction of L.
pneumophila replication, as compared to wild-type amoebae.
Again, these results are in agreement with the notion that the
advanced hits compounds target an alternative factor or factors
to calcineurin.
Thermophoresis assays were then carried out in an attempt
to evaluate the capability of the initially identiﬁed hits to bind
to the human calcineurin−calmodulin complex. However, out
of 12 compounds tested, only 2 showed a potential binding
with a Kd value at high micromolar concentration range,
indicative of weak, possibly nonspeciﬁc interactions (Table S4).
Finally, to determine the eﬀects of the advanced hits
compounds (Figures 3E and 4) on the activity of mammalian
calcineurin in vitro, recombinant human calcineurin was
assayed using a phosphate release kit (Figure 5H). To this
end, calcineurin-mediated phosphate release from an enzyme-
speciﬁc peptide was measured and normalized to vehicle (full
activity) and EGTA (no activity). Addition of the advanced hits
compounds only slightly decreased calcineurin activity in vitro,
and the changes were not statistically signiﬁcant. In summary,
the above results indicate that the advanced hits compounds
identiﬁed in this study do not aﬀect calcineurin but target
another, as yet unidentiﬁed, factor or factors.
■ DISCUSSION
This study presents a hit ﬁnding and chemical space exploration
analysis of compounds identiﬁed as inhibitors of intracellular
replication of L. pneumophila, using A. castellanii as a model
host system. We used hits identiﬁed in the Sinergia library,
comprising more than 1200 compounds that were assembled
based on a virtual screening with query compounds known to
target distinct pathogen pathways. The rationale behind the
design of this library was to increase the hit rate in a low-
throughput screen. Among the hits identiﬁed, we chose to focus
on a family of compounds sharing chemical similarities with
inhibitors of the calcineurin protein phosphatase enzyme
(Figures 1B and 2−4).
The majority of hits and corresponding advanced hits
compounds were originally derived from CN585, a small
molecule which speciﬁcally binds to and inhibits the catalytic
calcineurin A subunit, sharing a binding region with cyclo-
sporin/Cyp18.26 Thus, we sought to determine whether
calcineurin indeed plays a role in their mechanism of action.
To this end, we used several established calcineurin modulators
such cyclosporin A, developed as an immuno-suppressant drug
due to the crucial role that calcineurin plays in T-cell activation
(Figure 5).33 Cyclosporin A is a cyclic nonribosomal peptide
originally isolated from a soil fungus.34 The compound has
been shown to inhibit calcineurin activity by forming a complex
with the phosphatase and an activating protein, cyclophilin.35
Treatment of D. discoideum with cyclosporin A or FK506
strongly inhibited cAMP-induced stalk cell formation and
reduced the expression of prestalk- and prespore-speciﬁc
transcripts, whereas the compounds had little eﬀect on the
growth and aggregation of the amoebae.36 Thus, D. discoideum
responds to cyclosporin A, and calcineurin is likely involved in
the development of the amoebae. On the other hand,
cyclosporin A did not aﬀect the intracellular replication of L.
pneumophila in amoebae (Figure 5A), indicating that
calcineurin is not involved in this process. Moreover, the
relatively high IC50 of cyclosporine A seen for the inhibition of
growth in macrophages (∼30 μM), as well as the antibiotic
activity observed both in this study (Figure 5A) and previously
published for Mycobacterium avium,37 also suggests that this is
not the case. Most likely, cyclosporin A acts as an antibiotic
compound, rather than calcineurin activity aﬀecting L. pneumo-
phila replication.
The calcineurin inhibitors quercetin and chlorogenic acid did
not aﬀect the intracellular replication of L. pneumophila;
therefore, calcineurin is not involved in the process and cannot
be the target of the compounds identiﬁed in this study (Figure
5B,C). Quercetin is a plant-derived ﬂavonoid molecule, which
has been reported to bind to and inhibit calcineurin,28 and
chlorogenic acid is a phenol found in green coﬀee-bean extract
and has been reported to activate calcineurin in a calmodulin-
dependent manner.38 Finally, calcineurin depletion in A549
cells (Figure 5D) or D. discoideum (Figure 5E) barely aﬀected
the intracellular replication of L. pneumophila. In summary,
several highly eﬀective compounds were developed by virtual
screening and optimization starting from compounds targeting
calcineurin. However, to the best of our knowledge, they do not
appear to aﬀect calcineurin, and thus, their precise mechanism
of action remains to be elucidated.39,40
A commonly used drug, FK506 (also known as tacrolimus),
indirectly inhibits calcineurin activity by binding to a separate
protein, FKBP, together forming a potent antagonist.27
Interestingly, the Legionella protein Mip (macrophage
infectivity potentiator) shares structural similarity to the
FKBP protein family, and Mip proteins are also known to
bind FK506.41 It has been shown that L. pneumophila Mip
deletion mutant strains exhibit signiﬁcantly decreased intra-
cellular replication and survival from the earliest stages of
uptake.42,43 One possibility is that the compounds, ostensibly
developed for calcineurin, are instead interfering with the
activity of interacting proteins such as eukaryotic FKBP or,
potentially, bacterial Mip.
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The majority of our hit compounds appeared most eﬀective
when present during the initial stages of infection, as opposed
to 15−30 min after infection, suggesting that they play a role in
phagocytic uptake and the initial establishment of the LCV.
Because the advanced hits compounds do not seem to alter the
LCV composition dramatically (Figure S1), the uptake process
itself might be targeted by the drugs. It is known that local
concentrations of calcium play an important role in the
initiation of phagocytosis, an important factor in L. pneumophila
uptake.44 It has also been observed that calcium-binding
proteins calnexin and calreticulin are localized to phagocytic
cups during L. pneumophila uptake, after which they are actively
recruited to the LCV membrane.30,31
We utilized A. castellanii as a model host cell due to the
robust reproducibility of results and its role as a natural
reservoir of L. pneumophila. One potential caveat of this model
is that compounds eﬀective in amoebae may not have the same
eﬃcacy in human macrophages. However, similar screens with
Burkholderia pseudomallei in D. discoideum indicated that results
transfer well to mammalian experiments.45 Analogously, we
have previously shown that amoebae allow the discovery of
novel antibiotic compounds with high eﬃcacy in macro-
phages.23,46 Our results reported in this study also indicated
that antivirulence compounds highly eﬃcacious in amoebae
were also eﬀective in macrophage cell lines, further supporting
the use of amoebae as a model system. Previously, murine J774
macrophages have been used to screen for antivirulence
compounds, blocking the translocation of eﬀector proteins
through the T4SS of L. pneumophila.47 In this study, the
screening of a collection of more than 2500 annotated
compounds (Biomol, NINDS, or Prestwick library) revealed
that a number of host cell factors involved in phagocytosis
promote translocation through the T4SS.
Antivirulence compounds are usually identiﬁed by searching
for inhibitors of a speciﬁc, well-characterized virulence system.
This type of strategy led to the discovery of compounds that
inhibit the expression of the autoinducer synthase gene pqsA,22
block the T3SS of Salmonella enterica typhimurium,48 or
prevent E. coli capsule production.49 An alternative approach, as
used in this study, is to conduct a wide-ranging screen against
complex host cell−pathogen interactions, thus identifying
active compounds showing eﬃcacy against the target pathogen
in this setting. Using a library of 640 FDA-approved
compounds with known targets, a similar approach has been
employed to determine antimicrobial drugs with eﬃcacy against
a range of intracellular bacteria replicating in human THP-1
macrophage-like cells.50 This study identiﬁed several inhibitors
of cholesterol homeostasis that interfere with the intracellular
replication of Coxiella burnetti and, to a lesser extent, also with
L. pneumophila. Moreover, compounds targeting cellular (G
protein-coupled receptor-dependent) signaling pathways, cal-
cium ﬂuxes, or sterol homeostasis also had a strong eﬀect on C.
burnetti intracellular replication. Thus, repurposing approved
drugs appears to be a promising strategy to identify novel
antibacterial therapeutics.
In summary, using a pathway-based virtually designed library
we performed a wide-ranging screen for antivirulence
compounds against L. pneumophila replicating in A. castellanii
amoebae. This study presents a hit ﬁnding and chemical space
exploration analysis of compounds identiﬁed as inhibitors of
intracellular bacterial replication. Following the identiﬁcation of
a cluster of hits tentatively targeting the host cell protein
phosphatase calcineurin, we developed several advanced hits
compounds with a strong antivirulence eﬀect. Notably, one
advanced hits compound, ZINC00615682, inhibited the
intracellular replication of L. pneumophila in A. castellanii with
a low IC50 of approximately 20 nM. In contrast to original
expectations, the compounds characterized did not appear to
target calcineurin. Future experiments are aimed at the
identiﬁcation of the direct targets of these compounds.
■ METHODS
Bacteria and Reagents. L. pneumophila wild-type JR3251
or the isogenic mutant ΔicmT lacking a functional Icm/Dot
T4SS,52 constitutively producing GFP,53 were grown on
charcoal yeast extract (CYE) plates or in ACES yeast extract
(AYE) medium,54 with 10 μg/mL chloramphenicol. For
infections, the bacteria were grown overnight in AYE at 37
°C to a ﬁnal OD600 of 3.0, at which stage they have reached the
transmissive, infectious phase. Murine RAW 264.7 macro-
phages (ATCC Tib-71, lab collection) and human A549 lung
carcinoma epithelial cells (ATCC CCL-185, lab collection)
were maintained in supplemented RPMI medium, A. castellanii
(ATCC 30234) in PYG medium, and Dictyostelium discoideum
in HL5 medium; all were passaged twice weekly. The D.
discoideum strains used were Ax2 wild type, and derivatives were
depleted for calcineurin A39 or calcineurin B40 or DH1 wild
type and an isogenic coronin A knockout strain,55 respectively.
Compounds of the Sinergia library were purchased from
various chemical suppliers (Table S5) and generally stored as
30 mM stock solutions in DMSO.
Legionella Extracellular Growth Assay. Extracellular
replication of L. pneumophila in the presence of compounds
was determined as follows. L. pneumophila were taken from
CYE plates after 3 days of growth and resuspended in 3 mL of
AYE at a ﬁnal OD600 of 0.02, matching the bacterial
concentration used for intracellular assays (see below).
Compounds of interest or vehicle controls (<0.5% DMSO,
which did not interfere with the assays) were diluted into these
cultures, which were then incubated on a rotating wheel
overnight at 37 °C. OD600 measurements were then taken, and
the values were normalized to the vehicle controls.
Legionella Intracellular Replication Assays. Intracellular
replication of L. pneumophila in phagocytes (A. castellanii, D.
discoideum, and macrophages) was assessed using previously
published protocols.23 In brief, the phagocytes were seeded into
96-well plates and infected (MOI 20) with GFP-producing L.
pneumophila. Infected cells were incubated at 25 °C (D.
discoideum), 30 °C (A. castellanii), or 37 °C (macrophages), and
the progress of replication was followed by the increase in GFP
ﬂuorescence over several days. Because the culture media used
for the eukaryotic host cells do not support the growth of L.
pneumophila, GFP ﬂuorescence accurately reﬂects intracellular
replication. Moreover, the correlation between GFP ﬂuores-
cence and bacterial growth in A. castellanii at 30 °C was
conﬁrmed by determining CFU after 3 days.
The small-molecule compounds to be tested were added
simultaneously, 30 min postinfection, or 30 min preinfection.
For “pretreatment” experiments, the cells were incubated with
the drugs for 30 min and washed three times with media after
the drugs were taken oﬀ, followed by the addition of the
bacteria.
Cytotoxicity Assay and Fluorescence Microscopy. The
cytotoxicity of compounds to eukaryotic host cells (A.
castellanii, D. discoideum, and RAW 264.7 macrophages) was
determined using the Alamar Blue or Presto Blue reagent (Life
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Technologies). To mimic the conditions found in the
intracellular replication assay, 96-well plates were set up as
described above, and uninfected triplicate wells were treated
with compound in 100 μL of LoFlo medium (ForMedium).
Plates were incubated for 6 to 24 h at 30 °C (A. castellanii), 23
°C (D. discoideum) or 37 °C (macrophages), after which 10 μL
of Alamar Blue reagent was added, and plates were incubated
for another 3 to 4 h. The ﬂuorescence at 595 nm was measured,
and data were normalized between 1 (treatment with LoFlo
alone) and 0 (SDS, total lysis of the cells). Means from each
individual experiment were then combined for analysis. D.
discoideum strains were prepared and imaged by confocal laser
ﬂuorescence microscopy as previously described using a Leica
SP5 confocal laser scanning microscope.56−58
Calcineurin Activity Assay. In vitro calcineurin activity
was assayed with kits from Enzo Life Sciences (BML-AK804)
and used according to the manufacturer’s instructions. Brieﬂy,
wells of a 96-well plate contained a mixture of calcineurin (40
U), calmodulin, RII phosphopeptide (ALVPIPGRFARRVpS-
VAAN, 0.75 mM), and compound (30 μM) or vehicle control
(<0.1% DMSO, which did not interfere with the assay).
Calcineurin activity was determined by phosphate release after
15 min at 30 °C via the change in color of malachite green
(BioMol-Green) reagent.
Thermophoresis Assay. Thermophoresis assays were
carried out by using the microscale thermophoresis technology.
Compounds were tested from 200 μM to 25 nM in buﬀer (10
mM HEPES, pH 8.0, 2 mM CaCl2, 100 mM NaCl, 5 mM
DTT, 1% glycerol, 5% DMSO, 0.05% Tween 20, 25 nM
calcineurin, and 25 nM calmodulin), where calmodulin was
labeled with NT-647-HNS (Nanotemper). Compounds were
screened using the following process: 5 μL of 50 nM
calmodulin was added to assay tubes, followed by 5 μL of
800 μM compound. Solutions were mixed, and serial dilutions
were made by adding 5 μL to the following tube. Each assay
tube then had 5 μL of 50 nM calcineurin added. Samples were
centrifuged for 5 min at 10 000g, and the ﬂuorescence within
the tubes was measured at 80% LED and 40−80% laser power.
Measurements were performed in at least triplicate experi-
ments. Secondary analysis screened for the interaction of 50
nM calmodulin with 500 nM−15 pM calcineurin, reported to
have a Kd of 45 (± 10) nM.
RNA Interference. The calcineurin subunit genes (PPP3CB
or PPP3R1) were depleted in A549 epithelial cells using the
siRNA oligonucleotides (Qiagen) indicated (Table S6) as
previously published.59,60 Brieﬂy, A549 cells were seeded in 96-
well plates and treated for 2 days with a ﬁnal concentration of
10 nM siRNA oligonucleotides. After oligonucleotide trans-
fection, the cells were infected with GFP-producing L.
pneumophila (MOI 10) grown for 21 h in AYE, centrifuged,
and incubated for 1 h. The infected cells were washed three
times with prewarmed RPMI medium, and replication was
determined by GFP ﬂuorescence 48 h postinfection using a
plate reader. Experiments were performed in triplicate, and
replication values were normalized to that of cells treated with
scrambled RNA (Allstars siRNA; Qiagen).
The calcineurin depletion eﬃciency was analyzed by Western
blot. To this end, A549 cells were incubated with siRNA
oligonucleotides for 48 h, trypsinized, washed, and subjected to
SDS-PAGE and Western blot. The nitrocellulose membranes
were blocked with BSA or fat-free milk, and antibodies against
the calcineurin catalytic subunit (PPP3CB, ThermoFischer
Scientiﬁc; 1:1000) or regulatory subunit (PPP3R1, Thermo-
Fischer Scientiﬁc; 1:1000−1:100), followed by an HRPO-
conjugated donkey antirabbit IgG antibody (GE Healthcare),
were used. GAPDH (Cell Signaling) served as a loading
control, and Qiagen AllStars oligonucleotides were used as a
negative control.
Design of a Pathways-Based Highly Diverse Chemical
Library (Sinergia Library). To design the Sinergia library,
several pathways involved in host−pathogen interactions, in
particular, those with a signiﬁcant pathogen/host selectivity
ratio, were targeted (manuscript in preparation). Eighteen
diﬀerent host- and pathogen-related pathways were examined
as potential pharmacological targets. Ligands/metabolites
known to interfere within these pathways were collected and
used as queries or search templates for launching a campaign of
ligand-based virtual screening (VS) from the ZINC database61
by means of ROCS, a tool from the OpenEye software
package.24 Active ligands/metabolites served as query mole-
cules to prepare pharmacophores for the ligand-based VS. The
following workﬂow was applied: (i) the ZINC leadlike database
composed of 2.5 × 106 compounds was screened, saving the
25 000 best hits for each query; (ii) hits were ranked according
to the ROCS TanimotoCombo score; (iii) the ﬁrst VS hit was
selected, followed by the next one if structurally dissimilar to
previous selections, using the Lingo method present in the
OpenEye VIDA program to increase the chemical diversity and
exploit the maximal chemical space of the ZINC leadlike
database; (iv) at least two analogs were chosen per series from
each screened pathway, saving 100 selected compounds to the
pool of potential antibacterial hits composing the physical
library for the experimental screen. Of the ∼1800 compounds
selected by the VS procedure (∼100 per each pathway), 1258
could be purchased and made up the ﬁnal Sinergia library.
Hits-Based Analogs Selection. Compounds resulting in
decreased intracellular L. pneumophila replication by over 50%
at the screening concentration (30 μM) were deﬁned as hit
candidates. The chemical space around the speciﬁc scaﬀolds
characterizing the hit candidates was explored, searching for
compounds with a chemical similarity, calculated by Tanimoto’s
metrics, of at least 70% as compared to hit candidates in the
ZINC database. Small libraries of hit-based analogs were
designed by visually inspecting and selecting compounds from
providers, using medicinal chemistry hypotheses such as
substitution patterns and isosteric replacements to deﬁne the
structure−activity relationships and to guide the improvement
of the compounds series.
Data Analysis. Data analysis was performed using Micro-
soft Excel and GraphPad Prism 5. To compare the eﬀect of
compound treatment on intracellular replication, ﬂuorescence
values were taken from the ﬁrst time point following entry into
the stationary phase. The results were then normalized such
that media-only wells (no bacteria) were 0 whereas vehicle-
treated wells were 1 (normal replication). The average of the
replicate wells (minimum of 3 per plate) was then plotted as
dose−response curves such that each individual point
represented the average of a single experiment. Compound
treatments were repeated a minimum of 3 times to control for
the increased variability of bacteria−host cell interactions. Lines
of best ﬁt and associated IC50 values were calculated for each
dose−response curve using the nonlinear ﬁt (log inhibitor
versus response, variable slope) function of Prism 5.
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